Omega-3 and omega-6 fatty acids play essential roles in human health, being widely used in the prevention and treatment of various conditions, such as cardiovascular diseases, inflammation, and metabolic disorders. However, their oral administration faces significant challenges, including low solubility, rapid oxidation, and low bioavailability, which limit their therapeutic efficacy. This article explores recent advances in oral drug delivery systems designed for polyunsaturated fatty acids, highlighting how innovative technologies, such as nanoemulsions, liposomes, microencapsulation, and solid lipid nanoparticles (SLNs/NLCs), can improve their stability, absorption and clinical performance. In addition, the main natural sources of these compounds, as well as their extraction and purification methods, and the challenges related to their absorption and metabolism are discussed. This narrative review was based mainly on a comprehensive search of peer-reviewed literature published between 2015 and 2025 in PubMed, Scopus, and Web of Science. The therapeutic benefits of these emerging approaches are analyzed by comparing conventional methods with modern delivery strategies to optimize the use of omega-3 and omega-6 in the body. Finally, the article outlines future perspectives and regulatory challenges associated with these technologies, highlighting their potential to revolutionize the administration of essential fatty acids and broaden their applications in medicine and nutrition.

Aging is a multifactorial process that progressively disrupts cellular and tissue homeostasis, affecting all organ systems at distinct rates and predisposing individuals to chronic diseases such as cancer, type II diabetes, and sarcopenia. Among these systems, skeletal muscle plays a central role in healthspan decline, yet the precise onset of its deterioration remains unclear. Most studies emphasize late-life models, overlooking the transitional phase of middle age, when initial alterations emerge. Evidence indicates that middle-aged muscle exhibits aberrant metabolism, impaired insulin sensitivity, and an early, gradual reduction in mass, suggesting that decline begins long before overt sarcopenia. This narrative review synthesizes current findings on linear and non-linear molecular biomarkers associated with the onset of skeletal muscle aging, aiming to improve early detection of muscular alterations and support the development of interventions that delay or prevent functional decline.

Introduction: Atherosclerosis is a central element in the pathogenesis of contemporary cardiovascular diseases. Atherosclerosis can be defined as a slowly progressive inflammatory process associated with several causal factors. The pathophysiological process is characterized by a complex inflammatory cascade, initiated by vascular endothelial injury, leading to vascular narrowing and hardening. Objective: To review the presence of a systemic inflammatory process through the analysis of interleukin-6 and tumor necrosis factor alpha (TNF-a) markers in the inflammatory tissue manifestations in different segments of the aorta. Method: An integrative review was carried out in the PubMed and Scielo databases. The search used the following keywords: "inflammation, atherosclerosis, type 2 diabetes mellitus, CD68, IL-6, THFa, endothelium" and their English versions. Inclusion criteria included review articles, experimental studies, and preclinical and clinical research, written in Portuguese and English and available in full text. The selected articles were analyzed based on the technologies discussed, future prospects and challenges mentioned, and diseases related to the article's central idea. Result: 63 articles were evaluated. Conclusion: Pro-inflammatory cytokines are examples of inflammatory markers with serological expression. Tissue inflammatory markers, such as CD68, the macrophage activation glycoprotein, identified through immunohistochemical analysis, can allow the assessment of the vascular inflammatory process, especially in the context of atherosclerosis.

Aging of skeletal muscle is traditionally defined by progressive loss of mass and strength; however, the early events that precede these outcomes remain poorly characterized. Here, longitudinal analyses revealed that impaired glucose tolerance arises at 12 months of age in Wistar rats, before detectable changes in body composition, circulating damage markers, or muscle mass. Structural loss was preceded by functional decline and structural disorganization between 15 and 18 months. Animals exhibited marked reductions in strength, mobility, and motor coordination, accompanied by extensive remodeling of muscle architecture, including a shift toward glycolytic fiber composition, extracellular matrix expansion, reduced capillarization, and increased structural heterogeneity. Early supplementation with n-3 polyunsaturated fatty acids, initiated at midlife, significantly improved glucose tolerance, reduced adiposity, and enhanced neuromuscular performance without increasing muscle mass. These functional benefits were paralleled by reduced markers of muscle damage and attenuation of histopathological alterations, indicating preservation of tissue organization rather than hypertrophic effects. Notably, a substantial fraction of these benefits persisted after cessation of supplementation, with animals displaying sustained metabolic and structural advantages at 18 months compared to age-matched controls. Collectively, these findings support a model in which skeletal muscle aging is driven by early loss of functional and structural efficiency rather than mass decline, and demonstrate that transient nutritional intervention can durably reprogram the trajectory of muscle aging. These results highlight a critical window of intervention and position n-3 supplementation as a strategy to induce persistent resilience against age-related functional deterioration. Abstract Figure:

Cancer is the second leading cause of death worldwide. Cancer cachexia is a multifactorial catabolic syndrome responsible for almost one third of cancer-related deaths. Drug repurposing has been used in oncological research and drugs like clenbuterol and metformin seem to be reasonable candidates in the context of cancer cachexia, because the former is a β₂-agonist that stimulates muscle gain and the latter has anti-inflammatory properties. The aim of this study was to assess the effects of a short-term treatment with metformin and clenbuterol, isolated or combined, on tumor growth and cancer cachexia parameters in Walker 256 tumor-bearing rats, a model of cancer cachexia. To this end, Wistar rats were separated into 8 groups and 4 of them were injected with Walker 256 tumor cells (W groups). Control (C) and W groups received the following treatments: metformin (M), clenbuterol (Cb), or metformin combined with clenbuterol (MCb). Body and tumor weight, metabolic parameters, and oxidative damage in the tumor were assessed. Compared to the C group, the W group showed body weight loss, hypoglycemia, hyperlactatemia, and hypertriacylglycerolemia. None of the treatments could reverse body weight loss, although they reversed the alterations of the assessed plasma metabolic parameters. Surprisingly, only clenbuterol alone reduced tumor weight. Hydrogen peroxide production and lipid peroxidation in tumor tissue was increased in this group. In conclusion, metformin and clenbuterol ameliorated metabolic cachexia parameters in Walker tumor-bearing rats, but only clenbuterol reduced the tumor weight, probably, through a lipid peroxidation-dependent cell death.

The Developmental Origins of Health and Disease framework proposes that environmental exposures during critical periods of development can shape physiological systems and influence the risk of chronic diseases later in life, including diabetes and metabolic syndrome. Most research on metabolic programming has focused on classical metabolic organs such as the liver, pancreas, and adipose tissue. However, skeletal muscle plays a central role in systemic glucose homeostasis and metabolic flexibility, accounting for the majority of insulin-stimulated glucose uptake in the body. Because muscle metabolism is closely regulated by neural activity through the organization of motor units, the development of the motor neuromuscular axis may represent an underexplored dimension of metabolic programming. This review examines evidence linking early-life metabolic environments to neuromuscular development and discusses how alterations in the maturation of motor neurons, neuromuscular junctions, and muscle fiber phenotype may influence long-term metabolic outcomes. Evidence from epidemiological studies, experimental models, and mechanistic research suggests that maternal metabolic disturbances, including hyperglycemia, obesity, and systemic inflammation, can influence fetal development through metabolic and inflammatory pathways affecting both neural and muscular components of the motor system. These findings support the hypothesis that the motor neuromuscular axis may represent a structural interface linking early developmental exposures to long-term metabolic regulation and risk of metabolic syndrome.